Fish oil triglycerides
As of the edition of 20 October 2026, Fish oil triglycerides is a drug: marketed, first approved in 2018 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Unknown
- Brand name
- Omegaven
- First approved
- 27 July 2018 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Fresenius Kabi
- Registered trials
- 45, 6 stopped early
- Disease areas
- Digestive system; Cancer; Inherited and neonatal; Blood and lymph; Immune system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 6 | 1 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 12 | 6 | 0 | 5 |
| Phase 3 | 7 | 7 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 45 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Fresenius Kabi | Originator and Lead sponsor of trials | 2018 to now |